Literature DB >> 2168352

Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors.

P J Miller1, R S Hassanein, P G Giri, B F Kimler, P O'Boynick, R G Evans.   

Abstract

Univariate and multivariate statistical analyses were used to examine the relationships between duration of survival and multiple variables in the presentation and treatment of 82 patients with high-grade gliomas (16 grade 3, 66 grade 4). The median survival time of the eight patients who received less than or equal to 40 Gy to the tumor bed was 16 weeks and was 17 weeks for the three who received between 40 and 50 Gy. Patients who received 50-60 Gy had a median survival time of 62 weeks, compared to 54 weeks in patients who received 60-70 Gy. These differences in median survival time were statistically significant between the extremes (p = 0.0001), as well as between the 40-50 Gy group and the 50-60 Gy group (p = 0.02). However, no significant difference could be detected between the groups receiving 50-60 Gy versus 60-70 Gy. Univariate analysis also identified preoperative performance status, age, histologic grade, extent of surgery, and seizure history as prognostic factors. Cox multivariate analysis was performed to identify variables that were significant in independently predicting duration of survival. Although contemporary studies have shown many variables to be significant in predicting survival, our analysis found that many of them were not independent predictors. The variables which independently predicted improved duration of survival were greater total radiation dose to the tumor bed (p less than 0.0001), superior preoperative performance status (p = 0.003), and grade 3 versus grade 4 (p = 0.04). Younger age at diagnosis was marginally significant (p = 0.07). In the group of 60 patients receiving greater than 50 Gy, a discriminant analysis was also performed. The patients were divided into two groups based on apparent clusters of survival times: greater than or equal to 60 weeks versus less than 60 weeks. The only variable that was found to be predictive of membership in the cluster with longer survival was the presence of seizure activity (p = 0.02). Although univariate and multivariate analyses both showed an apparent statistically significant improvement in survival with increasing total radiation dose to the tumor bed, no additional benefit could be demonstrated for doses greater than 60 Gy.

Entities:  

Mesh:

Year:  1990        PMID: 2168352     DOI: 10.1016/0360-3016(90)90534-q

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  The conditional survival statistics for survivors with primary supratentorial astrocytic tumors.

Authors:  S L Hwang; Y H Yang; A S Lieu; M C Chuang; S J Chang; Y Y Chang; H J Lin; S L Howng
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

2.  Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas.

Authors:  E C Halperin
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

3.  The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.

Authors:  Meral Y Sayin; Bektas Kaya; Bekir H Bakkal; Kadri Altundag; Muzaffer B Altundag
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

4.  Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article.

Authors:  Kaisorn L Chaichana; Aditya N Halthore; Scott L Parker; Alessandro Olivi; Jon D Weingart; Henry Brem; Alfredo Quinones-Hinojosa
Journal:  J Neurosurg       Date:  2010-06-04       Impact factor: 5.115

5.  Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme--a quantitative radiological analysis.

Authors:  Jens P Schneider; Christos Trantakis; Matthias Rubach; Thomas Schulz; Juergen Dietrich; Dirk Winkler; Christof Renner; Ralf Schober; Kathrin Geiger; Oana Brosteanu; Claus Zimmer; Thomas Kahn
Journal:  Neuroradiology       Date:  2005-06-11       Impact factor: 2.804

6.  Postoperative radiotherapy for supratentorial malignant gliomas.

Authors:  S A Yeh; S W Leung; L M Sun; C J Wang; F M Fang; H C Chen
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

7.  Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme.

Authors:  Anna Rosati; Pietro Luigi Poliani; Alice Todeschini; Manuela Cominelli; Daniela Medicina; Marco Cenzato; Edda Lucia Simoncini; Stefano Maria Magrini; Michela Buglione; Salvatore Grisanti; Alessandro Padovani
Journal:  Neuro Oncol       Date:  2013-02-14       Impact factor: 12.300

8.  Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme.

Authors:  G Klautke; M Schütze; I Bombor; R Benecke; J Piek; R Fietkau
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

9.  Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Authors:  Suja Saraswathy; Forrest W Crawford; Kathleen R Lamborn; Andrea Pirzkall; Susan Chang; Soonmee Cha; Sarah J Nelson
Journal:  J Neurooncol       Date:  2008-09-23       Impact factor: 4.130

10.  Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts.

Authors:  Tomoko Ozawa; Sergei M Gryaznov; Lily J Hu; Krisztina Pongracz; Raquel A Santos; Andrew W Bollen; Kathleen R Lamborn; Dennis F Deen
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.